AR-42 (previously known as OSU-HDAC42; Arno Therapeutics) has been shown to have potent HDAC-inhibitory activity, which inhibit the GP130/STAT3 pathway to inhibit multiple myeloma cell growth62. The gene discussed is HDAC9; the disease is plasma cell myeloma.